Sex: U
Vaccine: TYP
Symptoms: Incomplete course of vaccination, Urinary tract infection
Clinical narrative: UTI (Urinary tract infection); Because of UTI patient was not able to continue the remaining doses of Vivotif; Case reference number US-BN-2023-010698 is a spontaneous case report initially received from a nurse via Company (reference number: USBAV23-2102) on 14-Dec-2023 and concerns a patient of unknown age and gender.  The patient's medical history and concomitant medication details were not provided.  On 07-Dec-2023, the patient took the first dose of Vivotif (batch number: unknown) at unknown dose, route and site of administration, for unknown indication.  As reported the patient had urinary tract infection (UTI) and because of urinary tract infection patient was not able to continue the remaining doses of Vivotif (explicitly coded as 'inappropriate schedule of vaccine administered').  On an unspecified date, the patient received treatment with antibiotics for the event urinary tract infection.  At the time of the initial report, the outcome of the event urinary tract infection was unknown.  The reporter assessed the event of UTI as non-serious and as possibly related to the administration of Vivotif.  Non-significant case correction performed on 21-Dec-2023 for the information received 15-Dec-2023:  Non-significant case correction performed on 21-Dec-2023 for the information received 14-Dec-2023: included confirmation of LRD.; Reporter's Comments: A patient of unknown age and gender experienced a non-serious event of urinary tract infection after the patient took the first dose of Vivotif, and as reported, because of urinary tract infection the patient was not able to continue the remaining doses of Vivotif, which is considered as inappropriate schedule of vaccine administered. Urinary tract infection is unlisted and unexpected for Vivotif according to the CCDS v1 and PI, whilst inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. The outcome of the event was unknown. Considering implied temporal relationship and since the contributory role of the suspect vaccine cannot be excluded with certainty, the event of urinary tract infection has been considered as related to Vivotif. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine. This case is considered as non-serious.; Sender's Comments: A patient of unknown age and gender experienced a non-serious event of urinary tract infection after the patient took the first dose of Vivotif, and as reported, because of urinary tract infection the patient was not able to continue the remaining doses of Vivotif, which is considered as inappropriate schedule of vaccine administered. Urinary tract infection is unlisted and unexpected for Vivotif according to the CCDS v1 and PI, whilst inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. The outcome of the event was unknown. Considering implied temporal relationship and since the contributory role of the suspect vaccine cannot be excluded with certainty, the event of urinary tract infection has been considered as related to Vivotif. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine. This case is considered as non-serious.